Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-30T21:17:19.842Z Has data issue: false hasContentIssue false
  • English
  • Français

Why Participate in an Alzheimer's Disease Clinical Trial? Is It of Benefit to Carers and Patients?

Published online by Cambridge University Press:  10 January 2005

Maree Mastwyk ,
Stephen Macfarlane ,
Dina LoGiudice  and
Karen A. Sullivan
Maree Mastwyk
Affiliation:
Mental Health Research Institute, Parkville, Australia Department of Pathology, University of Melbourne, Parkville, Australia
Stephen Macfarlane
Affiliation:
Mental Health Research Institute, Parkville, Australia Department of Pathology, University of Melbourne, Parkville, Australia
Dina LoGiudice
Affiliation:
Melbourne Extended Care and Rehabilitation Service, National Aging Research Institute, Prkville, Australia
Karen A. Sullivan
Affiliation:
School of Psychology and Counselling, Queensland University of Technology, Carseldine, Australia.
Get access

Abstract

Background: We explored carer motivation for seeking participation for a relative in an Alzheimer's disease (AD) clinical drug trial, to assess impressions of the value of trial participation. We also surveyed the carers of patients who did not meet study entry screening criteria to see if our conduct of the screening visit was acceptable and ethical. Method: A retrospective questionnaire was sent to the carers of 36 randomized participants and 22 carers of patients who did not meet study entry screening criteria for an AD clinical treatment trial. Results: Twenty-nine (81%) of the trial participant carers and 15 (68%) of carers of the group who did not meet study entry criteria returned their questionnaires with sufficient information for analysis. The prime motivators in seeking trial participation were to help their relative feel better and live longer, to contribute to medical science, to improve the health of others, and the hope of a cure. Carers of both groups found research staff supportive and would recommend trial participatiion to others. Conclusions: Even though trial participation is onerous and patients were generally perceived by carers as not having improved, both the screening visit and participation in the trial itself were seen as positive experiences and the expectations of carers were met.

Keywords

Alzheimer's diseaseclinical trialscarer perceptionsmotivationsupportresource
Type
Articles
Information
International Psychogeriatrics , Volume 15 , Issue 2 , June 2003 , pp. 149 - 156
Copyright
© 2003 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)